With continuously improving performance, Aiwei Technology welcomes concentrated research from institutional investors.

Publication Time:

2024-07-17 16:19

Source:

The company's performance growth trend is obvious, its technological leading edge continues to be consolidated, and Aiwei Technology, the leader in automated microscopy, has attracted concentrated research from institutional investors.

On the morning of July 16, Aiwei Technology held a concentrated reception event at its company park, with more than 20 representatives from renowned institutional investors such as Hunan Qingyan Venture Capital Management Co., Ltd., Hunan Huazhou Investment Private Equity Fund, Hunan Fu Chuan Private Equity Investment Fund, and Founder Securities and Sheng Investment participating in the research.

That day, Aiwei Technology's chairman Ding Jianwen, vice general manager and acting secretary of the board Lin Changqing, and chief financial officer Long Kunxiang and other senior executives introduced the company's recent achievements in R&D innovation and high-quality development, and actively interacted with the participating institutional investors, fully demonstrating the style of a sci-tech innovation board company from Hunan province.

Hunan-listed company invites auditing firm to participate in investor exchange for the first time

It is noteworthy that Tianjian Certified Public Accountants LLP Hunan branch also participated in the exchange as a host in this research activity and actively answered investor questions. This is the first time a Hunan-listed company has invited an auditing firm to participate in a face-to-face investor exchange.

The presence of Tianjian Certified Public Accountants LLP at Aiwei Technology's investor exchange event not only helped participating investors further understand the company's finances and internal governance, but also represents an important step in the high-quality development of the Hunan capital market.

It is understood that well-known multinational companies such as Apple, Microsoft, and Nvidia have long invited auditing firms to participate in investor exchange activities held by their companies.

Industry insiders point out that encouraging auditing firms to directly face market investors is beneficial for investors to understand listed companies from multiple dimensions, and will also allow auditing firms to intuitively feel the responsibility of "gatekeepers," promoting a "two-way rush" between Hunan institutions and local enterprises, helping companies attract more "patient capital".

In addition, the China Securities Regulatory Commission recently issued "Eight Measures to Deepen the Reform of the Sci-Tech Innovation Board and Serve Scientific and Technological Innovation and New High-Quality Productivity Development" (hereinafter referred to as the "Eight Measures for Sci-Tech Innovation"), further deepening reform, enhancing inclusiveness of new industries, new formats and new technologies, giving full play to the functions of the capital market, and better serving the overall situation of Chinese-style modernization. Aiwei Technology's concentrated reception of institutional investors is also a response to the "Eight Measures for Sci-Tech Innovation." Through exchange activities involving private equity funds, industry funds, and industry experts, a lot of suggestions from the capital market can be brought to listed companies on the Sci-Tech Innovation Board, helping enterprises strengthen corporate governance, optimize business strategies, and even discover opportunities for industrial investment and development, further promoting the development of new high-quality productivity.

Industry-leading automated microscopy technology, obvious performance growth trend

Data shows that Aiwei Technology is a pioneer and leader in automated microscopy technology in China. By applying "artificial intelligence + machine vision technology + big data" to the morphological examination of clinical specimens in medical and health institutions, Aiwei Technology has filled the technical gap in related fields both domestically and internationally, promoting the development of the industry from manual microscopy to automated microscopy.

Currently, in the field of automated microscopy, Aiwei Technology's product line has expanded from initial urine testing to multiple testing areas such as feces, gynecology, body fluids, and blood. At the same time, the company continues to deepen the clinical application of "artificial intelligence" and "machine vision technology," and the leading edge of its key core technologies continues to be consolidated.

Data shows that Aiwei Technology has led or participated in the development of 5 national industry standards, 2 local standards, and 2 group standards.

To date, the company's medical testing instruments have accumulated more than 15,000 sets of installations in China, and have accumulated terminal installations in more than 6,000 hospitals nationwide. Many of the company's leading products, such as the AVE-76 series, AVE-56 series, and AVE-32 series, for urine testing, stool testing, and reproductive tract secretion testing, have been widely recognized by customers and are in a market-leading position.

While achieving market leadership in instruments, Aiwei Technology actively develops supporting reagents and consumables products. While ensuring the accuracy of testing, this also opens up diversified sales sources for the company, forming a virtuous profit model in which instrument promotion drives the sales of supporting reagents and consumables, laying a solid foundation for the company's continued growth.

Financial reports show that Aiwei Technology's 2023 revenue exceeded 200 million yuan, a year-on-year increase of 1.79%; net profit attributable to the parent company reached 21.5338 million yuan, a year-on-year increase of 19.81%; and non-net profit was 12.4809 million yuan, a year-on-year increase of 98.98%.

In the first quarter of this year, the company's operating performance continued its growth trend, achieving revenue of 46.8138 million yuan, a year-on-year increase of 14.46%; and net profit attributable to the parent company of 5.0718 million yuan, a significant year-on-year increase of 136.42%.

Breakthroughs in multiple business areas expand growth space

In its more than 20 years of development, Aiwei Technology has always adhered to the core strategy of "innovation-driven development." As a pioneer and leader in automated microscopy technology both domestically and internationally, the company has been focusing on achieving automated microscopic morphological testing in medical testing since its establishment. This leading edge in key common technologies is the company's core competitiveness, and perfecting and developing key core technologies, expanding the application scope of products, and maintaining a leading position in this niche market is the foundation of the company's existence. Based on this core technology, the company's product line has expanded from initial urine testing to multiple testing areas such as feces, gynecology, body fluids, and blood. The company's new generation of urine modular analysis pipeline products, "1+2" and "2+4," and fully automated blood analysis pipeline products are in a market-leading position, with good market prospects, and are expected to become growth points for the company's performance.

It is understood that another key development strategic direction of the company is the primary and civilian medical market. On the one hand, targeting the characteristics of small scale, small sample size, and low automation requirements of primary medical and health institutions, the company has developed small, multifunctional instrument products to meet the clinical testing needs of primary medical and health institutions; on the other hand, targeting the civilian medical market of chronic disease management, health monitoring, and home self-testing, it has developed dozens of lightweight POCT/iPOCT products covering various aspects such as women's health, scientific pregnancy, childhood diarrhea, early tumor screening, gastrointestinal diseases, urinary system diseases, diabetes, and health checkups. With the launch and market expansion of the primary and civilian product lines, it is expected to become an important growth point for the company's future business.

In addition, increasing efforts to develop overseas markets and increase international business revenue is also an important focus for the company's future development.